<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942354</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTECAL-PRO</org_study_id>
    <nct_id>NCT03942354</nct_id>
  </id_info>
  <brief_title>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</brief_title>
  <acronym>PRACTECAL-PRO</acronym>
  <official_title>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medecins Sans Frontieres, Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sussex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Doris Goodwin Hospitals, Kwazulu Natal, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Don McKenzie Hospitals, Kwazulu Natal, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Republican specialised scientific-practical medical centre, Tashkent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Republican TB Hospital No. 2, Nukus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medecins Sans Frontieres, Netherlands</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant
      Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient
      perspective in terms of their quality of life, shared decision making and satisfaction with
      services.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tolerability of drugs for TB is a complex and dynamic course for patients with drug
      resistance and can be affected by many different factors. A deeper understanding of the
      perspectives and experience of men and women participating in novel TB treatment trials will
      add to the understanding of the safety and efficacy of treatment.

      TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating
      exclusively oral 6 months regimens containing bedaquiline, pretomanid, linezolid +/-
      moxifloxacin or clofazimine for the treatment of microbiologically confirmed pulmonary
      M/XDR-TB. It is registered with the ClinicalTrials.gov with identifier number NCT02589782.
      The trial aims to recruit 630 adults from two sites in Uzbekistan (Nukus and Tashkent) and
      one site each from Belarus and South Africa.

      The TB-PRACTECAL trial assumes that even if the investigational arms would have non-inferior
      efficacy and safety compared to the standard of care outcomes, patients would prefer a
      shorter, exclusively oral regimen with a lower pill count. This study therefore aims to
      describe patient experiences (i.e. the quality of the treatment experience as opposed to the
      quantity of treatment or the amount of time spent on it).

      The PRACTECAL-PRO sub-study aims to answer the question: &quot;What are the perceptions,
      expectations and experiences of novel TB treatment for adult patients participating in a
      six-month regimen clinical trial in Uzbekistan, South Africa and Belarus?&quot;

      The objectives for the analysis are:

        -  To compare baseline scores between trial patients (all interventional arm patients plus
           standard of care patients) with healthy controls.

        -  To assess changes in scores over time in patients on the intervention arms and patients
           on the standard of care arm.

        -  To assess the utility of the SF 12 and SGRQ in a TB clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in St George's respiratory questionnaire SGRQ survey questionnaire from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the quality of life (QoL) of trial patients from baseline to 12 months: both those treated in the investigational arms and the standard of care arm. For the SGRQ, a change of 4 points is suggested to indicate a clinically significant change, although the questionnaire was developed with patients who had COPD rather than TB. In the sub-study with a relatively small sample we cannot be confident about whether a change of 4 points represents a similarly significant change, but we will be mindful to assess this possibility. Ultimate aim is to determine whether disease-specific patient quality of life scores improve in investigational arm patients from baseline to successful completion of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Short form 12 survey questionnaire (patient satisfaction and experience) from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). Ultimate aim is to determine whether disease-specific patient satisfaction scores improve in investigational arm patients from baseline to successful completion of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Sirturo</other_name>
    <other_name>R207910</other_name>
    <other_name>TMC207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>PA-824</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Avelox, BAY 12-8039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Directly observed therapy (DOT)</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients recruited into the TB-PRACTECAL trial in the approved sites OR

          -  Local healthy-controls of a similar profile in terms of age and gender aged â‰¥18 years
             AND

          -  Literate in the study questionnaire languages

          -  Able to sign the sub-study informed consent form after agreeing to the additional
             interviews and completion of questionnaires.

        Exclusion Criteria:

          -  TB patients excluded from TB-PRACTECAL clinical trial

          -  Healthy volenteers with co-morbidities

          -  Healthy volenteers found to have TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Stringer</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Douch</last_name>
    <phone>+4402074046600</phone>
    <phone_ext>+4402074046600</phone_ext>
    <email>emma.douch@london.msf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <contact>
      <last_name>Animesh Sinha, MD</last_name>
      <phone>+375 297030902</phone>
      <email>minsk-ct-mtl@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Varvara Solodovnikova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doris Goodwin Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronelle Moodliar</last_name>
      <phone>0333980054</phone>
      <email>R.moodliar@thinksa.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Don McKenzie Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronelle Moodliar</last_name>
      <phone>033 3980054</phone>
      <email>R.moodliar@thinksa.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS,MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican TB Hospital No. 2</name>
      <address>
        <city>Nukus</city>
        <state>Karakalpakstan</state>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <contact>
      <last_name>Misa Sha</last_name>
      <email>NukusCT-crc@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Tigay N Zinaida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital</name>
      <address>
        <city>Tashkent</city>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <contact>
      <last_name>Mateus Sahani</last_name>
      <phone>+998 93 388 11 21</phone>
      <email>tashkent-crc-msf-oca &lt;tashkent-crc@oca.msf.org&gt;</email>
    </contact>
    <investigator>
      <last_name>Irina Liverko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>South Africa</country>
    <country>Uzbekistan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life, drug-resistant tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

